• Salasa

  Led · Series B · Aug 2025

  Salasa provides turnkey e-commerce fulfilment and logistics services spanning warehousing, inventory management, last-mile delivery, bonded zones, and cross-border shipping. Founded in 2017 and based in Riyadh, it integrates with platforms such as Salla, ZID, Amazon, Trendyol, and Shopify and partners with carriers including Aramex, DHL, and Saudi Post. Since inception Salasa has fulfilled and shipped over 50 million products and serves more than 1,000 merchants, including Noon, Amazon, Cenomi, Boutiqaat, Laverne, Sharaf DG, and Alothaim Retail. The company is transitioning into an AI-powered logistics platform to enable predictive, automated, and self‑optimising operations across planning, inventory, and fulfilment. Funds will be used to expand its fulfilment network, dark stores, and bonded zone capabilities and to boost international shipping to open new markets for merchants across the GCC and beyond. As Saudi Arabia’s e-commerce market grows, Salasa aims to scale its technology, physical footprint, and talent to become a tech-first logistics partner.

• FlyAkeed

  Participated · Series A · Sep 2023

  FlyAkeed operates a SaaS platform that automates travel booking and expense management for corporate customers and travel managers. The platform adopts a traveler-centric model linking travel policy, online booking, and expense management to create a seamless omni-channel experience. Features include an automated approval process, real-time expense management reports, extensive travel inventory, and a variety of travel-led employee benefits. FlyAkeed enables businesses to manage and track employee travel expenses to streamline processes and reduce costs. The company was founded in 2017 by Bassam AlMohammadi and is headquartered in Saudi Arabia. Following its Series A raise, FlyAkeed plans to expand its offering to more cities in Saudi Arabia and across the GCC and to explore fintech products and solutions to further enhance the travel experience for individual and enterprise users.

• Oncoinvent

  Participated · Equity · May 2020

  Oncoinvent is a clinical-stage company developing radiopharmaceutical technology that delivers alpha-emitting particles to treat metastatic solid cancers. Its lead candidate, Radspherin®, is a radium-224 based alpha-emitting microsphere suspension in ongoing Phase 1 trials for peritoneal carcinomatosis from ovarian and colorectal cancer. The company leverages internal manufacturing and supply-chain capabilities to enable clinical supply of radioisotopes and is advancing a pipeline of targeted radiotherapeutics. Proceeds from the recent financing will fund two planned Phase 2A studies (ovarian and colorectal cancer) and accelerate preclinical development of proprietary antibodies OI-1 and OI-3 by about one year. Oncoinvent has raised NOK 535 million to date and says the new proceeds secure financing past the end of 2023. The company intends to pursue a contemplated initial public offering within the coming twelve months. Oncoinvent is an Oslo, Norway–based developer of new products to provide treatment options to cancer patients. Its lead candidate, Radspherin®, is a radium-224–based, alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Preclinical studies have shown anticancer activity at doses that were essentially non-toxic. The company will use the funds from the financing to pursue clinical development of Radspherin® and to advance other novel radiopharmaceuticals. Oncoinvent is led by CEO Jan A. Alfheim and is focused on translating its preclinical results into clinical programs. No revenue or user metrics were reported in the article. Oncoinvent is an Oslo, Norway–based developer of cancer therapeutics led by CEO Jan A. Alfheim. Its lead product, Radspherin™, is a novel alpha-emitting radioactive microsphere based on radium designed for treatment of metastatic cancers in body cavities. Preclinical studies of Radspherin showed consistent anticancer activity without any visible signs of product-related toxicity. The company plans to pursue clinical development, with the first clinical indication being treatment of peritoneal carcinomatosis originating from ovarian cancer. Financially, Oncoinvent raised around $25m in new equity funding to support its development programs. Backers in the round included Geveran Trading, Canica, CGS Holding, Helene Sundt and Must Invest.

No current team members are available.